Mark Adelson

2.6k total citations · 1 hit paper
45 papers, 1.9k citations indexed

About

Mark Adelson is a scholar working on Surgery, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Mark Adelson has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 14 papers in Reproductive Medicine and 11 papers in Obstetrics and Gynecology. Recurrent topics in Mark Adelson's work include Ovarian cancer diagnosis and treatment (14 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Cervical Cancer and HPV Research (5 papers). Mark Adelson is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Endometrial and Cervical Cancer Treatments (7 papers) and Cervical Cancer and HPV Research (5 papers). Mark Adelson collaborates with scholars based in United States, Australia and Canada. Mark Adelson's co-authors include Stephen D. Williams, Vinay K. Malviya, Ernest W. Franklin, David S. Alberts, Robert V. O’Toole, James A. Young, Brent DuBeshter, Edward V. Hannigan, P. Y. Liu and William J. Hoskins and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mark Adelson

43 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

1996 906 citations David S. Alberts, P. Y. Liu et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Mark Adelson

Since Specialization

Citations

This map shows the geographic impact of Mark Adelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Adelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Adelson more than expected).

Fields of papers citing papers by Mark Adelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Adelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Adelson. The network helps show where Mark Adelson may publish in the future.

Co-authorship network of co-authors of Mark Adelson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Adelson. A scholar is included among the top collaborators of Mark Adelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Adelson. Mark Adelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bond Insurance: Introducing a Better Business Model 2015 ·Mark Adelson, (unknown)	2
2	Adenocarcinoma In Situ Arising in Vulvar Papillary Hidradenoma: Report of 2 Cases 2008 ·International Journal of Gynecological Pathology ·Sejal Shah, Mark Adelson, Michael T. Mazur	15
3	Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study 1999 ·Gynecologic Oncology ·Jonathan S. Berek, Maurie Markman, (unknown), Samuel S. Lentz, Mark Adelson, Koen DeGeest, David H. Moore	42
4	Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer breakdown → 1996 ·New England Journal of Medicine ·David S. Alberts, P. Y. Liu, Edward V. Hannigan, Robert V. O’Toole, Stephen D. Williams, James A. Young, Ernest W. Franklin, Daniel L. Clarke‐Pearson, Vinay K. Malviya, Brent DuBeshter, Mark Adelson, William J. Hoskins	906
5	A Phase II Trial of Merbarone (NSC 336628) in the Treatment of Recurrent Epithelial Ovarian Carcinoma 1996 ·American Journal of Clinical Oncology ·Katherine Y. Look, John A. Blessing, Mark Adelson, Michael A. Bookman, Mitchell Morris	8
6	Evaluation of the polymerase chain reaction for the detection of human papillomavirus from urine 1995 ·Journal of Medical Virology ·(unknown), Betty A. Forbes, Mark Adelson	33
7	Brachial plexus neuropathies after advanced laparoscopic surgery 1993 ·Fertility and Sterility ·(unknown), Harry Reich, F McGlynn, Mark Adelson, Patrick J. Taylor	46
8	A Phase II Trial of Vincristine in Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study 1993 ·American Journal of Clinical Oncology ·G. O. Broun, John A. Blessing, Gary L. Eddy, Mark Adelson	16
9	Aging and Development of Ovarian Epithelial Carcinoma: The Relevance of Changes in Ovarian Stromalandrogen Production 1993 ·Advances in experimental medicine and biology ·Margaret A. Thompson, Mark Adelson	11
10	Effects of Gonadotropin-Releasing Hormone Analogues on Ovarian Epithelial Tumors 1993 ·Clinical Obstetrics & Gynecology ·Mark Adelson, (unknown)	14
11	Squamous cell carcinoma of the endometrium presenting as peritonitis with small bowel obstruction 1992 ·Gynecologic Oncology ·Mark Adelson, (unknown)	2
12	Necrotizing fasciitis: A complication of squamous cell carcinoma of the vulva 1991 ·Gynecologic Oncology ·Mark Adelson, (unknown), (unknown)	2
13	Lupron Retards Proliferation of Ovarian Epithelial Tumor Cells Cultured in Serum-Free Medium 1991 ·The Journal of Clinical Endocrinology & Metabolism ·Margaret A. Thompson, Mark Adelson, (unknown)	45
14	Herpes Simplex and Human Papillomavirus Genital Infections: Controversy over Obstetric Management 1990 ·Clinical Obstetrics & Gynecology ·Newton G. Osborne, Mark Adelson	7
15	Phase II trial of vinblastine in advanced ovarian carcinoma 1990 ·Investigational New Drugs ·Gregory P. Sutton, John A. Blessing, Mark Adelson, Parviz Hanjani	3
16	Long-term Effects of Sterilization on Women 1989 ·Journal of Gynecologic Surgery ·Mark Adelson, William L. Graves, (unknown)	1
17	A ten-year experience treating cervical intraepithelial neoplasia with the CO2 laser 1989 ·American Journal of Obstetrics and Gynecology ·Michael S. Baggish, James H. Dorsey, Mark Adelson	52
18	Appraising a clinical journal article in obstetrics and gynecology 1989 ·American Journal of Obstetrics and Gynecology ·David B. Seifer, Mark Adelson, Raja W. Abdul‐Karim, Michael S. Baggish	5
19	Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma. 1988 ·PubMed ·Margaret A. Thompson, Mark Adelson, Lawrence M. Kaufman, Linda Marshall, (unknown)	24
20	Combined tubal and molar pregnancy: Case report 1988 ·American Journal of Obstetrics and Gynecology ·Eddie H. M. Sze, Mark Adelson, Michael S. Baggish, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact